Floatz logo

Cixutumumab

Synovial Sarcoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Synovial Sarcoma cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 2BB
Pembrolizumab
Valo Therapeutics Oy
Phase 2B
Imatinib
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B

View all 35 →

Same molecule, other indications

Cixutumumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative · Phase 2
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative · Phase 2
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →